logo
  Join        Login             Stock Quote

VIVUS (VVUS) Shares Surge After Qsymia Update

 January 07, 2013 10:39 AM
 


(By Balachander) VIVUS Inc. (NASDAQ: VVUS) shares soared in Monday early trade after the biopharmaceutical company disclosed a jump in prescriptions shipped for weight-loss drug Qsymia.

The company said Qsymia prescriptions shipped was 12,978 for the four-weeks ended Dec. 21, up 67.5 percent from 7,749 in the comparable period ending Nov.23.

Qsymia was approved by the U.S. Food and Drug Administration (FDA) in July 2012, with sales launched on September 17.

In the four-week period ended Oct. 26, Qsymia prescriptions shipped was 5,394, a regulatory filing showed.

For the third quarter Sept. 30, the company posted a net loss of $40.4 million or 40 cents a share, compared with a loss of $8.6 million or 10 cents a share in the same period last year. Net product revenue from prescriptions shipped was $41,000.

[Related -Aetna Inc (AET) & Coventry Health Care, Inc. (CVH): Game Changer]

Health insurer Aetna (NYSE: AET) had late last year decided to provide coverage for Qsymia.

The stock, which has been trading in the 52-week between $9.86 and $31.21, traded 9.67 percent higher at $15.07 at 10.37 am ET on Monday.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageTwo Firms On The Cusp Of A Major Turnaround

When a company stumbles repeatedly, investors eventually throw in the towel and sell their shares. read on...

article imagePick a Valid Strategy, Stick With It

I’m not going to argue for any particular strategy here. My main point is this: every valid strategy is read on...

article imageHow to Prepare For A Correction Without Missing Out On Upside Potential

Recent market commentary is starting to remind me of the periods in 2000 and 2008 just before the bottom read on...

article imageBritain’s Boom Can Still Zoom

Don’t overthink the disconnect between strong UK GDP and wobbly UK stocks. Economic fundamentals should win read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.